Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VVUS: VIVUS INC. (NASDAQ) -- Ignore unavailable to you. Want to Upgrade?

To: blankmind who wrote (5923)	3/17/1998 7:54:00 AM
From: g.w. barnard	Read Replies (4) \| Respond to of 23519

we got it: gw MOUNTAIN VIEW, Calif.--(BW HealthWire)--March 17, 1998--VIVUS Inc. (NASDAQ:VVUS) today announced approval by the Medicines Control Agency of the United Kingdom (MCA) to begin commercial production and shipment of MUSE(R) (alprostadil) from its new 90,000 square foot Lakewood, New Jersey facility. "This regulatory milestone will allow VIVUS to ship MUSE manufactured in our new US facility to Astra AB for distribution in the United Kingdom, and upon registration, to additional European countries," said Carol Karp, Vice President of Regulatory Affairs. "The existing plant will continue to supply MUSE to the United States, and other countries which rely on the US Food and Drug Administration (FDA) for clearance." Founded in 1991, VIVUS, Inc. is a leader in the development of advanced therapeutic systems for the treatment of erectile dysfunction, commonly referred to as impotence. VIVUS has pioneered a novel therapy for erectile dysfunction known as the transurethral system for erection. This therapy consists of a proprietary, non-invasive drug delivery system that delivers pharmacologic agents via the urethra. CONTACT: VIVUS Nina W. Ferrari or David Yntema, 650/934-5200 KEYW

To: blankmind who wrote (5923)	3/17/1998 9:12:00 AM
From: Don Dunlap	Read Replies (3) \| Respond to of 23519

Blankmind <<- Concerning the impact of the "at-risk" product of the new plant on 1st 1/4 results: they won't be included as revenue. The costs won't drag down earnings either - rather - look for them to show up in "Inventory." Inventory will go from $9 mill to $13 or $14 mill.>> If the costs won't drag down earnings this quarter, what IS dragging down earnings? Several posters on this board suggested that earnings would be negative because VVUS was running a new facility with no corresponding revenue. The costs won't be recognized until the product is sold, and neither will the revenue. I imagine the costs of building the plant are capitalized, so that should not affect revenue either. These costs will affect cash flow, but not earnings. So, where are all the costs coming from that will cause VIVUS to lose money? Is it because they are shipping product to Astra for less than the cost of production? Or is it to pay for advertising>